Efficacy and safety of Yukmijihwang-tang in patients with type 2 diabetes who have microalbuminuria- a pilot study

Daegu Catholic University Medical Center0 个研究点目标入组 30 人开始时间: 待定最近更新: 2019年3月11日

适应症

试验速览

暂无简介。

•Patients are eligible to be included in the study only if they meet all of the following criteria;
•? Subject who is more than18 years of age and younger than 80 years of age has been diagnosed with type 2 diabetes mellitus.
•? Subject who have micromabumiuria (30-300mg/day)
•? Subject agrees to participate in this study and writes Informed consent.

•Patient will be excluded from the study if they meet any of the following criteria;
•?Subject has a Hb A1c value more than 9%, hyperglycemia or symptom due to poorly controlled glucosefor at least 3 months, and should be required more intense medications based on the investigator's judgement.
•?Subjects is currently receving or changing Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
•?Subject is participating in another clinical study.
•?Subject has a history of an active malignancy, Chronic kidney disease stage 4 or more, serious conditions such as hepatic or heart disease
•?Subject is the female of childbearing potential who are pregnant, breast-feeding, or not using adequate contraceptive methods
•?Subject currently has a history of severe physical activity, fever, elevation of blood pressure, or high protein diet.
•?Subject has episodes of nausea, vomiting, or acute gastrointestinal symptom within the 2 weeks before

发起方

Daegu Catholic University Medical Center